Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment.

Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment. Br J Dermatol. 2020 Aug 06;: Authors: Napolitano M, Caiazzo G, Fabbrocini G, Balato A, Di Caprio R, Scala E, Scalvenzi M, Patruno C Abstract Atopic dermatitis (AD) and psoriasis (Pso) are chronic diseases that may be phenotypes at polar ends of the T-cell inflammatory milieu.1,2 The two diseases represent two distinct pathogenetic entities, with type 2 T helper (Th2) cytokines interleukin (IL)-4, IL-13, IL-31, and possibly IL-22 mainly implicated in AD, and Th17 cytokines IL-17 and IL-23 in Pso.3 However, a range of phenotypes with overlapping clinical patterns exist, possibly reflecting a variable expression of T-cell axes. PMID: 32762038 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research